SHANGHAI – Huya Bioscience International, with offices in San Diego, Tokyo and eight more across China, has set up its first China joint venture (JV) with the Tianjin Institute of Pharmaceutical Research (TIPR). The new entity is seeking to develop innovative therapeutics as well medical devices for China and global markets.
BEIJING – Two Chinese biotech companies are forming an alliance to bring a safer and more effective novel treatment for colorectal, breast and ovarian cancer patients in China.
HONG KONG - Researchers from the Chinese University of Hong Kong (CUHK) have identified a small-molecule compound that dramatically inhibited tumor growth in a mouse model of hepatocellular carcinoma (HCC), representing a promising lead candidate for further investigation as an urgently needed new class of HCC therapy.
HONG KONG – China is gradually moving toward a new medicine distribution system where pharmacies and external retailers take over sales of prescription drugs from hospitals. The gradual change could ultimately eliminate "commissions" for doctors and hospitals.
SHANGHAI – BGI, a powerhouse gene sequencing organization based in China, and the Vancouver Prostate Centre agreed to formalize their relationship by establishing a joint translational cancer research laboratory in Vancouver, British Columbia. They will use genome research to develop new biomarkers and cancer therapies, initially focusing on drug-resistant forms of bladder, kidney and prostate cancers.
HONG KONG - Treatment with cholesterol-lowering statins has been shown to induce partial recovery of bone growth in mouse models of dwarfism, suggesting those agents could be useful for the medical treatment of infants and children with growth disorders such as achondroplasia and thanatophoric dysplasia.
BEIJING – A new scheme to improve and boost the development of Shanghai's biopharmaceutical industry that will take effect at the end of this month should generate opportunities for local biopharmaceutical enterprises, especially the bigger ones.
Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., said Leverkusen, Germany-based Bayer Healthcare's Japanese subsidiary, Bayer Yakuhin Ltd., received approval in Japan for Eylea (aflibercept) injection for myopic choroidal neovascularization.
SHANGHAI – After a 15-month corruption investigation, the verdict for Glaxosmithkline plc in China has been guilty as charged, surprising few industry insiders; it is routine for the government to come out on top in such high-profile cases, while most readily admit there are no saints in China's downstream pharmaceutical business.
RSS